Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 14, Issue 1, pp 21–25 | Cite as

Pharmacokinetics of amsacrine in patients receiving combined chemotherapy for treatment of acute myelogenous leukemia

  • J. L. Jurlina
  • A. R. Varcoe
  • J. W. Paxton
Original Articles Amsacrine

Summary

The pharmacokinetics of amsacrine have been studied after the first and third infusions (200 mg·m-2) in 10 patients receiving combined chemotherapy for the treatment of acute myelogenous leukaemia (AML). Postinfusion amsacrine elimination was best described by a biexponential expression with a mean t1/2α of 0.8 h and a terminal t1/2β of 5.3 h. After the third infusion there was a significant reduction (P<0.05) in the plasma clearance (Cl) and a prolongation of the terminal half-life (t1/2β) (P<0.01), but no change in the initial half-life (T1/2α) or volume of distribution (Vd). No significant overall changes were recorded in any of the biochemical indices of renal or hepatic function between the first and third infusions, but the patient who exhibited the largest reduction in Cl showed a marked increase in AST levels and a reduction in albumin concentration. Two distinct groups were apparent after the first infusion, patients with a Cl>294 and those with a Cl<208 ml·h-1·kg-1. The latter patients were significantly older (P<0.05), and four of the five had subnormal albumin concentrations. Urinary determination of amsacrine indicated that renal elimination plays a minor role in the total clearance of this drug. Amsacrine was also found to be highly bound to plasma proteins (96.4%–97.7%), but changes in binding were not responsible for the reduced Cl and prolonged t1/2β observed between the first and third infusions. We suggest that the elimination of amsacrine may be susceptible to small changes in hepatic function, perhaps due to the high amsacrine concentrations (5–18 μmol·l-1) achieved with this regimen, which may be approaching saturation of the capacity for hepatic elimination.

Keywords

Leukemia Plasma Protein Distinct Group Minor Role Large Reduction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Arlin ZA, Flomenberg N, Gee TS, Kempin SJ, Dellaquila C, Mertelsmann R, Straus DJ, Young CW, Clarkson BD (1981) Treatment of acute leukaemia in relapse with 4′-(9-acridinylamino) methanesulphon-m-anisidide (AMSA) in combination with cytosine arabinoside and thioguanine. Cancer Clin Trials 4: 317Google Scholar
  2. 2.
    Arlin ZA, Gee TS, Mertelsmann R, Kempin SJ, Reich LM, Straus DJ, Miggins C, Clarkson BD (1983) Randomized trial of 4′(9-acridinylamino) methanesulfon-m-anisidide (AMSA) in combination with cytosine arabinoside (ARA-C) and thioguanine (TG) vs daunorubicin with ARA-C and TG in adults with acute non-lymphoblastic leukaemia (ANLL). In: Amsacrine. Current perspectives and clinical results with a new anti-cancer agent. Communications Media for Education, New Jersey, p 977Google Scholar
  3. 3.
    Atwell GJ, Cain BF, Seelye RN (1972) Potential Antitumour agents. 12. 9-Anilinoacridines. J Med Chem 15: 611Google Scholar
  4. 4.
    Cain BF, Atwell GJ (1974) The experimental antitumour properties of three congeners of the acridylmethane-sulphonanilide (AMSA) series. Eur J Cancer 10: 539Google Scholar
  5. 5.
    Cain BF, Seelye RN, Atwell GJ (1974) Potential Antitumour agents. 14. Acridylmethanesulphonanilides. J Med Chem 17: 922Google Scholar
  6. 6.
    Cysyk RL, Shoemaker D, Adamson RH (1971) The pharmacological disposition of 4′-(9-acridinylamino) methanesulfon-m-anisidide in mice and rats. Drug Metab Dispos 5: 579Google Scholar
  7. 7.
    Gibaldi M, Perrier D (1975) In: Pharmacokinetics. Marcel Dekker, New York, p 69Google Scholar
  8. 8.
    Goldman A, Malpas JS (1982) Phase I and II study of AMSA in childhood tumours. Cancer Chemother Pharmacol 9: 53Google Scholar
  9. 9.
    Hall SW, Friedman J, Legha SS, Benjamin RS, Gutterman JU, Loo TL (1983) Human pharmacokinetics of a new acridine derivative, 4′-(9-acridinylamino) methanesulfon-m-anisidide (NSC 249992). Cancer Res 43: 3422Google Scholar
  10. 10.
    Jacquillat C (1983) Amsacrine in acute leukaemia: In: Amsacrine. Current perspectives and clinical results with a new anti-cancer agent. Communication Media for Education, New Jersey, p 41Google Scholar
  11. 11.
    Jurlina JL, Paxton JW (1983) A high-performance liquid chromatographic method for the determination of 4′-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in plasma. J Chromatogr 276: 367Google Scholar
  12. 12.
    Legha SS, Keating MJ, Zander AA, McCredie KB, Bodey GP, Freireich EG (1980) 4′(Acridinylamino) methanesulfon-m-anisidide (AMSA): A new drug effective in the treatment of adult acute leukaemia. Ann Intern Med 93: 17Google Scholar
  13. 13.
    Legha SS, Keating MJ, McCredie KB, Bodey GP (1982) Evatuation of AMSA in previously treated patients with acute leukaemia: Results of therapy in 109 adults. Blood 60: 484Google Scholar
  14. 14.
    Lima JJ, Boudoulas H, Blanford M (1981) Concentration-dependence of disopyramide binding to plasma protein and its influence on kinetics and dynamics. J Pharmacol Exp Ther 219: 741Google Scholar
  15. 15.
    Malspeis L, Khan MN, Blat HB (1979) HPLC determination of 4′-(9-acridinylamino)methanesulfon-m-anisidide (M-AMSA) (NSC 249992) in the plasma of a patient with hepatic dysfunction. Proc Am Assoc Cancer Res 20: C384 (abstract 383)Google Scholar
  16. 16.
    Metzler CM (1969) NONLIN. A computer program for parameter estimation in non-linear situations. Upjohn (Biostatistics Dept), KalamazooGoogle Scholar
  17. 17.
    Micetich KC, Zwelling LA, Gormley P, Young RC (1982) Phase I–II study ofm-AMSA administered as a continuous infusion. Cancer Treat Rep 66: 1813Google Scholar
  18. 18.
    Paxton JW, Jurlina JL (1984) Determination of the anti cancer drug amsacrine in biological fluids by HPLC. In: Methodological surveys in biochemistry and analysis, vol 14. Reid E, Wilson ID (eds) Drug determination for therapeutic and forensic appraisals. Plenum Press, London (in press)Google Scholar
  19. 19.
    Rivera G, Evans WE, Dahl GV, Yee C, Pratt CB (1980) Phase I clinical and pharmacokinetic study of 4′-(9-acridinylamino)methanesulfon-m-anisidide in children with cancer. Cancer Res 40: 4250Google Scholar
  20. 20.
    Sedman AJ, Wagner JC (1974) AUTOAN. A decision-making pharmacokinetic computer programme. Publication Distribution Service, University of Michigan Medical Center, Ann ArborGoogle Scholar
  21. 21.
    Staubus A, Neidhart J, Young D, Malspeis L (1980) Pharmacokinetics ofm-AMSA (NSC 249992) in humans. Proc Am Assoc Cancer Res 21: 198 (abstract 793)Google Scholar
  22. 22.
    Tan CTC, Hancock C, Steiherz PG, Steinherz LJ, Sorell M, Chan KW, Mondora A, Miller DR (1982) Phase II study of 4′-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992) in children with acute leukaemia and lymphoma. Cancer Res 42: 1579Google Scholar
  23. 23.
    Van Echo DA, Chiuten DF, Gormley PE, Lichtenfield JL, Scotlock M, Wiernik P (1979) Phase I clinical and pharmacological study of 4′(9-acrinylamino)methanesulfon-m-anisidide using an intermittent by-weekly schedule. Cancer Res 39: 3881Google Scholar
  24. 24.
    Von Hoff DD, Howser D, Gormley PE, Bender RA, Glaubiger D, Levine AS, Young RC (178) Phase I study of methanesulfon-amide,N-[4-(9- acidinylamino)-3-methoxy phenyl] (m-AMSA) using a single-dose schedule. Cancer Treat Rep 62: 1421Google Scholar
  25. 25.
    Weick JK, Jones SE, Ryan DH (1983) Phase II study of amsacrine (m-AMSA) in advanced lymphomas: A Southwest Oncology Group Study. Cancer Treat Rep 67: 489Google Scholar
  26. 26.
    Winton EF, Hearn EB, Vogler WR, Johnson L, Logan T, Raney M (1983) Amsacrine in refractory adult acute leukaemia: a pilot study of the Southeastern Cancer Study Group. Cancer Treat Rep 67: 977Google Scholar

Copyright information

© Springer-Verlag 1985

Authors and Affiliations

  • J. L. Jurlina
    • 1
  • A. R. Varcoe
    • 2
  • J. W. Paxton
    • 1
  1. 1.Department of Pharmacology and Clinical PharmacologyUniversity of Auckland School of MedicineAucklandNew Zealand
  2. 2.Department of HaematologyAuckland HospitalAucklandNew Zealand

Personalised recommendations